Camzyos Adolescent Data Positive, But BMY's Thesis Hinges on Eliquis and Margins

What happened

Bristol Myers Squibb's drug Camzyos has shown strong late-stage clinical results for treating adolescent heart disease, potentially expanding its use in the cardiovascular portfolio. This news comes as BMY's overall cardiovascular segment faces mixed developments, including policy headwinds and legacy product declines. Camzyos is part of BMY's Growth Portfolio, which reported a 59% sales increase to $353 million in Q4'25, indicating ongoing momentum. However, the DeepValue report highlights that BMY's investment thesis centers on Eliquis growth and gross margin stability during the 2026 transition year. While positive, this Camzyos data does not directly address the core risks of Eliquis pricing pressures and gross margin fragility outlined in recent filings.

Implication

The expanded indication for Camzyos may enhance its revenue contribution, yet it remains a small part of BMY's portfolio compared to Eliquis. Investors must scrutinize whether this growth is achieved without compromising margins, as the DeepValue report warns that upside depends on stable gross margins, not just sales increases. This development does not alter the critical need to monitor Eliquis' ability to meet its 2026 growth guide amid policy changes. Consequently, the news reinforces BMY's growth portfolio strength but does not mitigate the broader risks tied to legacy erosion and margin pressures. Awaiting quarterly results for confirmation on Eliquis and gross margins remains essential before adjusting investment decisions.

Thesis delta

The positive Camzyos data reinforces BMY's growth portfolio momentum but does not shift the core investment thesis, which remains contingent on Eliquis achieving its 2026 growth target while maintaining gross margins in the 69-70% range. Investors should continue to prioritize monitoring these key metrics, as any deviation could significantly impact valuation, and no material change to the 'WAIT' rating is justified until such confirmation is evident.